Hot flashes and GSM in breast cancer survivors
Also known as:
Menopause symptoms after breast cancer
Managing vasomotor and genitourinary symptoms safely alongside oncology care.
Written and reviewed by Farhan Tahir, MD · Last reviewed
VIDEO LESSON
Vasomotor symptoms
• Systemic hormone therapy is generally avoided
• Venlafaxine, gabapentin and oxybutynin are common choices
• Avoid paroxetine and fluoxetine with tamoxifen (CYP2D6 inhibition)
• Elinzanetant was studied in women on endocrine therapy in OASIS-4 (NEJM 2025), with regulatory review of this use ongoing in 2026
• CBT and hypnosis help
Genitourinary symptoms
• Start with moisturizers, lubricants and pelvic floor therapy
• Low-dose vaginal estrogen may be considered after shared decision-making with oncology, particularly with tamoxifen
• Extra caution with aromatase inhibitors, whose benefit depends on very low estrogen levels
The evidence
Large observational cohorts have not shown higher breast cancer-specific mortality with vaginal estrogen use, but data in aromatase inhibitor users remain limited.
Key studies and references
Educational content only, written and reviewed by Farhan Tahir, MD. It does not replace individual medical advice. For sudden chest pain, trouble breathing or stroke symptoms, call 911.
AT A GLANCE
Section
Prescribing
Also known as
Menopause symptoms after breast cancer
Reviewed by
Farhan Tahir, MD
Keep exploring
Prescribing
Prescribing menopausal hormone therapy after the label change
A practical framework for systemic HT: who benefits, which formulation, and what changed on the label.
Read the guide →
Diagnosis & monitoring
Diagnosing perimenopause without labs
Age and cycle pattern make the diagnosis after 45. When labs help, and the mimics to exclude.
Read the guide →
Prescribing
Non-hormonal options for vasomotor symptoms
Evidence and monitoring for fezolinetant, elinzanetant, paroxetine and other non-hormonal therapies.
Read the guide →